Dynamic pathology of islet endocrine cells in type 2 diabetes: β-Cell growth, death, regeneration and their clinical implications

Journal of Diabetes Investigation

Volumn 7, Issue 2, 2016, Pages 155-165

  Yagihashi, Soroku ^a   Inaba, Wataru ^a   Mizukami, Hiroki ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Islet; Pathology; Type 2 diabetes

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; AMYLOID; INSULIN;

ARTICLE; AUTOPHAGY; CELL CYCLE; CELL DAMAGE; CELL DEATH; CELL DENSITY; CELL DIVISION; CELL GROWTH; CELL LOSS; CELL MATURATION; CELL REGENERATION; CELL TRANSDIFFERENTIATION; CELL VOLUME; DISEASE SEVERITY; ENDOPLASMIC RETICULUM STRESS; ETHNIC DIFFERENCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL HYPERPLASIA; PRIORITY JOURNAL; BIOLOGICAL MODEL; CELL AGING; CELL PROLIFERATION; COMPLICATION; HYPERGLYCEMIA; HYPERPLASIA; METABOLISM; PANCREAS ISLET; PATHOLOGY; REGENERATION;

AMYLOID; CELL PROLIFERATION; CELLULAR SENESCENCE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPERPLASIA; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MODELS, BIOLOGICAL; OBESITY; REGENERATION;

EID: 84959473901     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12424     Document Type: Article

References (65)

1. Langerhans P. Beiträge zur mikroskopischen Anatomie der Bauchspeicheldruse. Med. Dissertation, Thesis, Gustav Lange, Berlin, 1869.
2. Banting FG, Best CH. Pancreatic extracts. J Lab Clin Med 1922; 7: 464-472.
3. Opie EL. On the relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of Langerhans. J Exp Med 1901; 5: 527-540.
4. Tompsett SL. The determination of blood sugar: critical analysis of the reduction of alkaline copper by glucose and other substances. Biochem J 1930; 24: 1148-1163.
5. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960; 39: 1157-1175.
6. Berson SA, Yalow RS. Immunochemical distinction between insulins with identical amino-acid sequences. Nature 1961; 30: 1392-1393.
7. Deckers JG, Schellevis FG, Fleming DM. WHO diagnostic criteria as a validation tool for the diagnosis of diabetes mellitus: a study in five European countries. Eur J Gen Pract 2006; 12: 108-113.
8. Sone H, Ito H, Ohashi Y, et al. Japan Diabetes Complication Study Group. Obesity and type 2 diabetes in Japanese patients. Lancet 2003; 361: 85.
9. Hsu WC, Boyko EJ, Fujimoto WY, et al. Pathophysiologic differences among Asians, native Hawaiians, and other Pacific Islanders and treatment implications. Diabetes Care 2012; 35: 1189-1198.
10. Mclean N, Ogilvie RF. Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes 1955; 4: 367-376.
11. Saito K, Yaginuma N, Takahashi T. Differential volumetry of A, B and D cells in the pancreatic islets of diabetic and nondiabetic subjects. Tohoku J Exp Med 1979; 129: 273-283.
12. Peters J, Jurgensen A, Kloppel G. Ontogeny, differentiation and growth of the endocrine pancreas. Virchows Arch 2000; 436: 527-538.
13. Gregg BE, Moore PC, Demozay D, et al. Formation of a human β-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab 2012; 97: 3197-3206.
14. Meier JJ, Butler AE, Saisho Y, et al. β-Cell replication is the primary mechanism subserving the postnatal expansion of β-cell mass in humans. Diabetes 2008; 57: 1584-1594.
15. Mizukami H, Takahashi K, Inaba W, et al. Age-associated changes of islet endocrine cells and the effects of body mass index in Japanese. J Diabetes Investig 2014; 5: 38-47.
16. Hulinky I, Hulinska H, Silink M. DNA synthesis in cultured neonatal rat islets-a comparison of two methods. Diabetes Res Clin Pract 1995; 27: 119-126.
17. Francis RJ, Southgate JL, Wilkin TJ, et al. Expression of an islet regenerating (reg) gene in isolated rat islets: effects of nutrient and non-nutrient growth factors. Diabetologia 1992; 35: 238-242.
18. Koyama M, Wada R, Sakuraba H, et al. Accelerated loss of islet βcells in sucrose-fed Goto-Kakizaki rats, a genetic model of non-insulin-dependent diabetes mellitus. Am J Pathol 1998; 153: 537-545.
19. Perl S, Kushner JA, Buchholz BA, et al. Significant human β-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab 2010; 95: E234-E239.
20. Kohler CU, Olewinski M, Tannapfel A, et al. Cell cycle control of β-cell replication in the prenatal and postnatal human pancreas. Am J Physiol Endocrinol Metab 2011; 300: E221-E230.
21. Meier JJ, Kohler CU, Alkhtib B, et al. β Cell development and turnover during prenatal life in humans. Eur J Endocrinol 2010; 162: 559-568.
22. Georgia S, Bhushan A. p27 Regulates the transition of β-cells from quiescence to proliferation. Diabetes 2006; 55: 2950-2956.
23. Sullivan BA, Hollister-Lock J, Bonner-Weir S, et al. Reduced Ki67 staining in the postmortem state calls into question past conclusions about the lack of turnover of adult human beta cells. Diabetes 2015; 64: 1698-1702.
24. Mizukami H, Takahashi K, Inaba W, et al. Involvement of oxidative stress, endoplasmic reticulum stress, and autophagy deficit in β cell decline in Japanese type 2 diabetic patients. Diabetes Care 2014; 37: 1966-1974.
25. Cnop M, Hughes SJ, Igoillo-Esteve M, et al. The long lifespan and low turnover of human islet β cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia 2010; 53: 321-330.
26. Cnop M, Igollo-Esteve M, Hughes SJ, et al. Longevity of human islet a- and β-cells. Diabetes Obes Metab 2011; 13(Suppl 1): 39-46.
27. Rieck S, Kaestner KH. Expansion of β-cell mass in response to pregnancy. Trends Endocrinol Metab 2010; 21: 151-158.
28. Hughes E, Huang C. Participation of Akt, menin, and p21 in pregnancy-induced β-cell proliferation. Endocrinology 2011; 152: 847-855.
29. Kloppel G, Anlauf M, Raffel A, et al. Adult diffuse nesidioblastosis: genetically or environmentally induced? Hum Pathol 2008; 39: 3-8.
30. Kaneto H, Matsuoka TA. Down-regulation of pancreatic transcription factors and incretin receptors in type 2 diabetes. World J Diabetes 2013; 4: 263-269.
31. Sakuraba H, Mizukami H, Yagihashi N, et al. Reduced β-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002; 45: 85-96.
32. Rhodes CJ. Type 2 diabetes-a matter of β-cell life and death? Science 2005; 307: 380-384.
33. Saisho Y, Elashoff D, Butler AE, et al. β-cell mass and turnover in humans. Effects of obesity and aging. Diabetes Care 2013; 36: 111-117.
34. Yabe D, Kuroe A, Watanabe K, et al. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. J Diabetes Complications 2015; 29: 413-421.
35. Kou K, Saisho Y, Satoh S, et al. Change in β-cell mass in Japanese nondiabetic obese individuals. J Clin Endocrinol Metab 2013; 98: 3724-3730.
36. Stefan Y, Orci L, Malaisse-Lagae F, et al. Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes 1982; 31: 694-700.
37. Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia 1983; 24: 366-371.
38. Yoon KH, Ko SH, Cho JH, et al. Selective β-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88: 2300-2308.
39. Butler AE, Janson J, Bonner-Weir S, et al. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
40. Rahier J, Guiot Y, Goebbels RM, et al. Pancreatic β-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008; 10(Suppl 4): 32-42.
41. Leibowitz G, Kaiser N, Cerasi E. β-Cell failure in type 2 diabetes. J Diabetes Investig 2011; 2: 82-91.
42. Yagihashi S. Clinical staging of type 2 diabetes. The time has come. J Diabetes Investig 2012; 3: 1-2.
43. Matveyenko AV, Veldhuis JD, Butler PC. Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. Diabetes 2006; 55: 2347-2356.
44. Menge BA, Tannapfel A, Belyaev O, et al. Partial pancreatectomy in adult humans does not provoke β-cell regeneration. Diabetes 2008; 57: 142-149.
45. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci USA 2010; 107: 16009-16012.
46. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012; 122: 4-12.
47. Henquin JC, Rahier J. Pancreatic α cell mass in European subjects with type 2 diabetes. Diabetologia 2011; 54: 1720-1725.
48. Talchai C, Xuan S, Lin HV, et al. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell 2012; 150: 1223-1234.
49. Mezza T, Muscogiuri G, Sorice GP, et al. Insulin resistance alters islet morphology in nondiabetic humans. Diabetes 2014; 63: 994-1007.
50. Yagihashi S, Mizukami H, Inaba W. Quo vadis: where have the β-cells gone? J Diabetes Investig 2015; 6: 393-395.
51. Clark A, Nilsson MR. Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? Diabetologia 2004; 47: 157-169.
52. Westermark P. Amyloid in the islets of Langerhans: thoughts and some historical aspects. Ups J Med Sci 2011; 116: 81-89.
53. Kamata K, Mizukami H, Inaba W, et al. Islet amyloid with macrophage migration correlates with augmented β-cell deficits in type 2 diabetic patients. Amyloid 2014; 21: 191-201.
54. Zhao HL, Lai FM, Tong PC, et al. Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes. Diabetes 2003; 52: 2759-2766.
55. Last NB, Rhoades E, Miranker AD. Islet amyloid polypeptide demonstrates a persistent capacity to disrupt membrane integrity. Proc Natl Acad Sci USA 2011; 108: 9460-9465.
56. Huang CJ, Lin CY, Haataja L, et al. High expression rates of human amyloid polypeptide induce endoplasmic reticulum stress mediated β-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 2007; 56: 2016-2017.
57. Hull RL, Zraika S, Udayasankar J, et al. Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress. Diabetologia 2009; 52: 1102-1111.
58. Rivera JF, Gurlo T, Daval M, et al. Human-IAPP disrupts the autophagy/lysosomal pathway in pancreatic β-cells: protective role of p62-positive cytoplasmic inclusions. Cell Death Differ 2011; 18: 415-426.
59. Jurgens CA, Toukatly MN, Fligner CL, et al. β-Cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 2011; 178: 2632-2640.
60. de Koning EJ, van den Brand JJ, Mott VL, et al. Macrophages and pancreatic islet amyloidosis. Amyloid 1998; 5: 247-254.
61. Donath MY, Dalmas E, Sauter NS, et al. Inflammation in obesity and diabetes.: islet dysfunction and therapeutic opportunity. Cell Metab 2013; 17: 860-872.
62. Eguchi K, Manabe I. Macrophages and islet inflammation in type 2 diabetes. Diabetes Obes Metab 2013; 63: 1698-1711.
63. Westwell-Roper CY, Ehses JA, Verchere CB. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1β production and beta cell dysfunction. Diabetes 2014; 63: 1698-1711.
64. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 2010; 11: 897-904.
65. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.